摘要
目的:探究带量采购及医疗服务价格调整对冠心病治疗成本及患者医疗负担的影响。方法:选取某三甲医院2020年1-5月及2021年1-5月置入冠状动脉支架的出院病种为研究对象,并对采集的数据进行独立样本t检验统计学分析。结果:冠状动脉支架带量采购及医疗服务价格调整后,支架使用人数、医疗总费用、医保统筹支付费用、个人支付费用均较调整前发生较大变化。与2020年相比,2021年置入一个支架、两个支架和三个及以上支架的人数均在增长,支架费用呈下降趋势。医疗服务价格进行合理优化后,患者的医疗总费用、医保统筹支付费用、个人支付费用呈明显下降态势。结论:耗材带量采购及医疗服务价格调整对冠心病治疗成本有较大的影响,是降低患者就医负担、优化医疗费用的有效途径。
Objective:Under the background of the purchase of drug consumables by volume and the price adjustment of medical services,the impact of coronaryheart disease cost and medical burden of patients was investigated.Methods:Discharged patients with coronary stents in a certain grade A tertiary hospital from January to May 2020 and January to May 2021 was selected as the research object,and the data collected was analyzed by statistical method of independent sample T test.Results:The number of stent users,to⁃tal medical expenses,medical insurance pooling fees and individual payment fees changed significantly after the adjustment of coro⁃nary artery stent volume procurement and medical service price.Compared with 2020,the study showed that there was an increase in the number of patients with one stent,two stents and three or more stents in 2021.It was found that the cost of stents demonstrated a downward trend.After the reasonable optimization of medical service price,the total medical cost of patients,medical insurance pool⁃ing fees and individual payment feespresented a downward trend as well.Conclusion:The purchase of drug consumables by volume and the price adjustment of medical services have great influence on the cost ofcoronary heart disease treatment,which is an effective way to reduce the burden of patients and optimize the entire hospital price system.
作者
夏静
万彬
王滢鹏
陈加玉
丁海霞
XIA Jing;WAN Bin;WANG Yingpeng;CHEN Jiayu;DING Haixia(Medical Insurance Department,Jiangsu People’s Hospital,Nanjing,Jiangsu,210000)
出处
《江苏卫生事业管理》
2022年第10期1360-1363,共4页
Jiangsu Health System Management
关键词
耗材带量采购
医疗服务价格调整
冠心病
成本
影响
Purchase of Drug Consumables by Volume
Price Adjustment of Medical Services
Coronary Heart Disease
Cost
Impact